ELTX

Elicio Therapeutics Inc.

NASDAQ: ELTX · HEALTHCARE · BIOTECHNOLOGY

$11.30

-5.20% today

Updated 2026-06-02

Market cap

$253.08M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.36

Dividend yield

—

52W range

$7 – $15

Volume

0.1M

Market cap

$253.08M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.36

Dividend yield

—

52W range

$7 – $15

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-16.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$17.50

+54.87%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity -3.39x — low leverage

Risks

- Altman Z -16.90 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-11.64M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-28.21M	$-35.20M	$-51.90M	$-39.57M	$-11.82M
EPS	—	—	—	—	$-2.36
Free cash flow	$-22.83M	$-32.76M	$-37.16M	$-36.97M	$-11.64M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ELTX	$253.08M	17	4.3	3.0	5.0	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Elicio Therapeutics Inc. trades at $11.30. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -16.90, it sits in the distress.

Frequently asked questions

What is Elicio Therapeutics Inc.'s stock price?

Elicio Therapeutics Inc. (ELTX) trades at $11.30.

Is Elicio Therapeutics Inc. overvalued?

Elicio Therapeutics Inc. carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Elicio Therapeutics Inc. (ELTX)?

The 12-month analyst consensus target is $17.50, about 54.9% above the current $11.30. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Elicio Therapeutics Inc.'s Altman Z-Score is -16.90, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-1,076.00%

Beta1.45

50D MA$10.89

200D MA$9.98

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ELTX vs LLY →ELTX vs JNJ →ELTX vs ABBV →Stock screener →